Profile data is unavailable for this security.
About the company
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
- Revenue in USD (TTM)684.00k
- Net income in USD-78.29m
- Incorporated2017
- Employees61.00
- LocationCG Oncology Inc400 Spectrum Center Drive, Suite 2040IRVINE 92618United StatesUSA
- Phone+1 (949) 288-6298
- Fax+1 (302) 531-3150
- Websitehttps://www.cgoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | 0.00 | -103.48m | 1.89bn | 74.00 | -- | 4.04 | -- | -- | -3.97 | -3.97 | 0.00 | 15.73 | 0.00 | -- | -- | 0.00 | -23.74 | -- | -24.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| MannKind Corp | 267.20m | 21.57m | 1.90bn | 414.00 | 97.02 | -- | 67.65 | 7.12 | 0.0711 | 0.0711 | 0.9277 | -0.7612 | 0.6812 | 2.79 | 13.36 | 645,410.60 | 5.50 | -26.07 | 7.00 | -37.80 | 71.91 | 59.68 | 8.07 | -57.61 | 4.17 | 1.89 | 1.77 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Beam Therapeutics Inc | 349.64m | -143.59m | 1.95bn | 436.00 | -- | 2.46 | -- | 5.58 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Mirum Pharmaceuticals Inc | 307.03m | -99.81m | 2.07bn | 311.00 | -- | 8.99 | -- | 6.76 | -2.12 | -2.12 | 6.51 | 4.84 | 0.4657 | 3.83 | 5.28 | 1,162,985.00 | -15.14 | -38.93 | -17.70 | -44.88 | 72.68 | -- | -32.51 | -190.71 | 3.15 | -- | 0.5701 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Wave Life Sciences Ltd | 53.61m | -142.52m | 2.09bn | 266.00 | -- | 15.03 | -- | 38.97 | -1.11 | -1.11 | 0.427 | 1.01 | 0.192 | -- | 15.32 | 201,541.40 | -51.04 | -56.98 | -99.07 | -102.38 | -- | -- | -265.84 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| CG Oncology Inc | 684.00k | -78.29m | 2.17bn | 61.00 | -- | 4.07 | -- | 3,171.45 | -1.19 | -1.19 | 0.0104 | 7.95 | 0.0018 | -- | 9.91 | 11,213.12 | -18.93 | -- | -19.63 | -- | -- | -- | -10,578.22 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Akero Therapeutics Inc | 0.00 | -237.22m | 2.18bn | 60.00 | -- | 2.94 | -- | -- | -3.75 | -3.75 | 0.00 | 10.61 | 0.00 | -- | -- | 0.00 | -32.66 | -37.73 | -34.35 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0454 | -- | -- | -- | -35.46 | -- | -- | -- |
| Keros Therapeutics Inc | 651.00k | -181.57m | 2.18bn | 160.00 | -- | 3.97 | -- | 3,350.11 | -5.21 | -5.21 | 0.0187 | 13.57 | 0.0014 | -- | -- | 4,786.77 | -40.10 | -35.95 | -42.23 | -38.07 | -- | -- | -27,890.94 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Azenta Inc | 656.32m | -164.17m | 2.23bn | 3.30k | -- | 1.17 | -- | 3.39 | -2.97 | -2.97 | 12.31 | 38.82 | 0.2633 | 3.23 | 3.71 | -- | -6.59 | -2.07 | -7.18 | -2.31 | 40.13 | 43.11 | -25.01 | -8.76 | 3.50 | -- | -- | -- | -1.32 | -3.41 | -1,174.32 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 19.65m | -538.64m | 2.27bn | 525.00 | -- | 6.87 | -- | 115.66 | -4.65 | -4.65 | 0.1701 | 2.66 | 0.0234 | -- | -- | 37,424.76 | -65.18 | -20.02 | -73.62 | -24.65 | -- | -- | -2,785.85 | -61.79 | -- | -154.93 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Ideaya Biosciences Inc | 3.92m | -178.12m | 2.30bn | 124.00 | -- | 1.95 | -- | 586.20 | -2.32 | -2.32 | 0.0515 | 13.67 | 0.0044 | -- | 1.17 | 31,629.03 | -20.09 | -19.17 | -20.87 | -21.05 | -- | -- | -4,541.56 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.48 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -131.16m | 2.36bn | 33.00 | -- | 8.47 | -- | -- | -3.31 | -3.31 | 0.00 | 6.45 | 0.00 | -- | -- | 0.00 | -72.82 | -53.90 | -82.94 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Geron Corp | 29.48m | -201.19m | 2.43bn | 141.00 | -- | 8.29 | -- | 82.43 | -0.3221 | -0.3221 | 0.0469 | 0.4846 | 0.0687 | -- | 1.31 | 209,078.00 | -46.90 | -51.32 | -63.81 | -64.90 | 97.29 | -- | -682.47 | -19,949.13 | 2.74 | -- | 0.2229 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Janux Therapeutics Inc | 13.05m | -60.54m | 2.44bn | 64.00 | -- | 3.71 | -- | 187.02 | -1.18 | -1.18 | 0.2548 | 12.54 | 0.0241 | -- | -- | 203,890.60 | -11.19 | -- | -11.53 | -- | -- | -- | -463.91 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to CG Oncology Inc's reporting currency: US Dollar USD
34.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.00m | 7.45% |
| Braidwell LPas of 30 Sep 2024 | 3.17m | 4.73% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.10m | 4.62% |
| Ally Bridge Group (NY) LLCas of 25 Jan 2024 | 2.49m | 3.72% |
| Kynam Capital Management LPas of 30 Sep 2024 | 1.77m | 2.64% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.70m | 2.54% |
| Avidity Partners Management LPas of 30 Sep 2024 | 1.66m | 2.47% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 1.51m | 2.26% |
| RA Capital Management LPas of 30 Sep 2024 | 1.40m | 2.08% |
| RTW Investments LPas of 30 Sep 2024 | 1.34m | 2.00% |
More ▼
Data from 25 Jan 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
